Replimune to Present at the Cantor Global Healthcare Conference 2026
Replimune will webcast its Cantor Global Healthcare Conference fireside chat for investors with a 30-day replay window.
Rhea-AI Summary
Replimune (REPL) will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET.
The presentation will be webcast live in the Investors section of Replimune’s website, with a replay available online for 30 days following the conference.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 19 | Inducement equity grants | Neutral | -5.1% | Company granted inducement options and restricted stock units to its chief commercial officer. |
| Aug 14 | Q1 2027 earnings | Positive | -1.4% | Quarterly loss narrowed while cash and financing proceeds supported more than twelve months. |
| Aug 10 | Underwritten offering | Negative | +13.3% | Company priced common shares and pre-funded warrants for aggregate gross proceeds. |
| Aug 06 | FDA accelerated approval | Positive | -6.2% | FDA authorized TUDRIQEV with nivolumab for advanced cutaneous melanoma patients. |
| Jul 30 | Advisory committee outcome | Positive | +107.0% | Advisory committee voted that IGNYTE efficacy results were evaluable and clinically meaningful. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Replimune's recent announcements showed inconsistent price alignment, including a negative reaction to the August 6 FDA approval and a positive reaction to the July 30 advisory-committee update.
Key Terms
oncolytic immunotherapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies, including the Company’s first commercially available product TUDRIQEV (vusolimogene oderparepvec-wtpg), approved under accelerated approval by the U.S. Food and Drug Administration in combination with nivolumab for the treatment of adults with advanced melanoma who experienced disease progression on a PD-1 antibody-based regimen. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. Upon intratumor injection, RPx causes direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens, alteration of the tumor microenvironment, and when dosed in combination with an immune checkpoint inhibitor immunotherapy, it may ignite a systemic anti-tumor response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
